Business Wire

Momcozy Survey Finds Moms Face Biggest Challenges of Time and Breast Pump Management, When Referring to Breastfeeding and Pumping Demands

23.2.2023 09:07:00 EET | Business Wire | Press release

Share

In a recent survey, Momcozy, the best-selling wearable breast pump brand in North America found that moms struggle with breastfeeding and breast pumping mostly due to a lack of time, space, and the right breast pump. In addition, wearable breast pumps that allow moms to pump hands-free anywhere to balance life enjoyment and nursing.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230222005522/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Momcozy Breastfeeding and Pumping Experience Survey results (Graphic: Business Wire)

The survey was conducted from July 25th, 2022- September 13th, 2022, via Momcozy’s social media accounts and newsletter targeting North American moms, and garnered nearly 1000 responses, which found:

  • Moms face many hurdles to successful breastfeeding, including breast health issues, latching problems, and isolation sense. The most common difficulty however was managing the time to pump around busy schedules, along with the difficulties of breast pump management.
  • Generally, moms with wireless, wearable pumps reported more positive pumping experiences compared with their traditional breast pump counterparts.
  • Most respondents pump at home, at work, or in transit, indicating moms spend most of their time between taking care of their child, and earning income.
  • In terms of the ‘craziest’ place moms ever breast pumped, the most mentioned locations included at meetings, the grocery store, parties, and restaurants. Other locations mentioned such as festivals, amusement parks and sports games indicate that for some moms, wearable breast pumps allow them greater flexibility and freedom to do things they like.

These findings suggest that every minute of breastfeeding and expressing moms counts. While expressing goals can still be difficult, wearable breast pumps allow moms to express comfortably anytime, anywhere with confidence and freedom. In short, mothers have little time to choose when and where to express for themselves. But with a hands-free, wearable breast pump, moms can feel more secure pumping anywhere without missing out on the fun of their lives.

The Momcozy S12 Pro Wearable Breast Pump was developed with the full understanding of mothers' feeding needs. It can be seamlessly integrated into the busy schedule of mothers, providing an efficient breastfeeding experience and long battery life support to meet the needs of breastfeeding in various scenarios.“Always put moms on top” is what Momcozy has been fulfilling. Through cozy designs born from love and continuous innovation, Momcozy brings a much simpler, more relaxed, and more comfortable experience for moms globally through their pregnancy and early motherhood.

About Momcozy

Momcozy, the renowned maternity and baby brand endorsed by over 2 million moms, is the best companion for moms globally through their pregnancy and early motherhood. Centering around wearable breast pumps, Momcozy offers a wide range of products covering nursing, clothing and textile, FMCG, security, and more to accompany moms through their pregnancy and early motherhood in a more comfy and convenient way, making it the choice of Gen Z and millennial moms.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Marketing Dept.
Ella Zheng
1-855-322-1777(Mon.-Fri. 8:30am-12:00pm;1:00pm-5:30pm PST)
ella.zheng@momcozy.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Capco Recognized by OpenAI for Innovation and Responsible AI Leadership26.6.2026 21:00:00 EEST | Press release

Global management and technology consultancy Capco, a Wipro company,has been recognized by OpenAI for both AI innovation and responsible AI leadership. Capco received the AI Governance & Risk Excellence Award at the recent OpenAI Partner Summit 2026 in San Francisco, highlighting Capco’s ability to deliver enterprise-grade AI outcomes in highly regulated environments. The award recognizes Capco’s expert advantage when helping financial services and energy organizations to scale AI with confidence, balancing innovation with strong governance to reduce risk, strengthen compliance and improve customer outcomes. This award follows Capco winning the OpenAI Codex Hackathon, where its UK AI Lab competed against more than 30 teams and over 100 participants from across the OpenAI partner ecosystem. Capco's winning entry Sentra – a consulting-led, AI-powered retail banking solution – uses digital twin technology to identify vulnerable customers and recommend explainable next-best actions for fro

Incyte Announces Positive CHMP Opinion for Opzelura ® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 14:30:00 EEST | Press release

Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids (TCSs) and topical calcineurin inhibitors (TCIs) are inadequate or inappropriate. “AD is a chronic skin condition that can have a significant impact on daily life. The positive CHMP opinion for Opzelura marks meaningful progress toward bringing the first non-steroidal topical JAK treatment option to adults in Europe with moderate AD for whom standard topical therapies have failed,” said Lee Heeson, Executive Vice President and Head of Incyte International. “If approved by the European Commission, Opzelura could help address an important gap for patients who have limited treatment options when TCSs and TCIs are inadequate or inappropriate.” The positive CHMP o

Datroway ® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 14:00:00 EEST | Press release

Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the TROPION-Breast02phase 3 trial, which werepresented at the 2025 European Society for Medical Oncology Congress and published in Annals of Oncology. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In TROPION-Breast02, Datroway demonstrated a

DAYBU ® (trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 13:49:00 EEST | Press release

Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating condition," said Catherine Owen Adams, Acadia’s Chief Executive Officer. “Our commitment is to make a meaningful difference in the lives of patients, caregivers, and the wider Rett com

HTEC Showcases Lakebase Branching at Databricks’ Data & AI Summit26.6.2026 12:18:00 EEST | Press release

HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. The Solution was developed in collaboration with a leading risk and compliance technology provider who serves financial institutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260626875859/en/ HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. Solving Critical Development Bottlenecks in Regulated Environments At the core of the collaboration was a shared challenge: how to enable modern data workflows in an envi

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye